臺灣博碩士論文加值系統

Apolipoprotein (ApoE) 被認為與阿茲海默症的主要病狀：神經突斑塊和神經纖維纏結的發生有關係，在人體中ApoE主要有三種對偶基因：E2、E3和E4這三種不同的isoforms具有不同的N-terminal domain以及相同的C-terminal domain，而N-terminal domain決定不同isoform的弁遄AApoE4被認為是造成晚發型阿茲海默症的危險因子，相反地，ApoE2與ApoE3則具有能抑制或延緩神經突斑塊的形成，然而，ApoE N-terminal domain的結構已知為4個?helix以反平行的方式組成束狀，但是其C-terminal domain之結構至今仍未知道，所以我們的研究目的為解出ApoE C-terminal domain之結構以及瞭解ApoE3與ApoE4在結構上之差異。我們首先純化出高純度同位素標定之ApoE C-terminal domain以供NMR分析它的立體空間結構，從結果可得知確實能在NMR分析下獲得正確的chemical shift，另外我們同時純化未標定之ApoE3和ApoE4 N-terminal domain期望能藉由NMR去探討不同的ApoE N-terminal domain 與其C-terminal domain之間的鍵結，目前protein已經純化完畢，並且將在進行NMR的研究。

Apolipoprotein E (ApoE) has been implicated in the formation of the extracellular neuritic plaques and the intracellular neurofibrillary tangles, which are highly associated with pathological severity of Alzheimer’s disease. In human, there are three APOE alleles, E2, E3 and E4, and the differences between isoforms are located at their amino terminal domains, which also determine the function of each ApoE isoform. ApoE4 is one of the risk factors determining the developing late-onset family of Alzheimer’s disease. In contrast, ApoE2 and ApoE3 could arrest extracellular neuritic plaques formation. The structure of ApoE N-terminal domain is consisted of a four-helix bundle with antiparallel arrangement, but the structure of the C-terminal domain remains unknown. The purpose of our studies is to analyze the structure of ApoE C-terminal domain and to determine the structural difference between ApoE3 and ApoE4. We obtained highly purified isotope-labeled ApoE C-terminal domain for NMR analysis. In addition, we also prepared the N-terminal domains of ApoE3 and ApoE4 for determination of the structural differences between ApoE isoforms by NMR analysis. At present, we had accomplished all the protein preparation and the NMR analysis is underway now.

中文摘要……………………………………………………………………….i
英文摘要………………………………………………………………………ii
目錄………………………………………………………………….iii
圖目錄………………………………………………………………………vi
表目錄…………………………………………………………….…vii
第一章 緒論………………………………………………………………….....1
第二章 實驗材料與方法…………………………………………………...…6
2-1 實驗材料………………………………………………………………..….6
2-1.1 化學藥品…………………………………………………………...…...6
2-1.2 M9培養液配方…………………………………...............................….6
2-1.3緩衝溶液之配置…………………………………………………..........8
2-1.4 Ni2+-column的製備……………………………………………….……9
2-1.5 C-18 column的平衡……………………………………………….…...9
2-2 實驗方法…………………………………………………………..……..10
2-2.1 質體pET32a-ApoE 195-299之構築………………………………...10
2-2.2 質體pET32a-ApoE 之構築………………………………………....10 2-2.3 DNA片段的回收或純化……………………………………….…..11
2-2.4 勝任細胞 (Competent Cell) 之制備…………………………....…...12
2-2.5 轉形 (transformation) 作用………………………………….….…...12
2-2.6 質體DNA之抽取………………………………………….…………12
2-2.7藉由定點突變 ( site-directed mutagenesis) 的方式構築pET32a- ApoE3N與pET32a-ApoE4N……………………………………..….……..13
2-2.8表達重組蛋白…………………………………………………......…...14
2-2.8a表達未標定之重組蛋白…………………………………………....14
2-2.8b表達具同位素15N、13C和2H標定之ApoE195-299 融合蛋…...15
2-2.8c表達具同位素15N和13C標定ApoE3N與ApoE4N融合蛋白.....15
2-2.9 透析及冷凍乾燥……………………………………………….......….16
2-2.10 重組蛋白的純化步驟………………………………………..…..…..16
2-2.10a 藉由Ni2+-column純化具有His-Tag 之重組蛋白…………...…16
2-2.10b 藉由thrombin的切割以切除融合蛋白…………………………17
2-2.10c 藉由Ni2+-column來純化不具有Tag之重組蛋白…….…….….17
2-2.10d 藉由HPLC來純化蛋白…………………………………….…...17
第三章 實驗結果.............................................................................................19
3-1 同位素15N、13C和2H標定ApoE195-299之製備……………………19
3-1.1 表達具同位素15N、13C和2H標定ApoE195-299 融合蛋白….…19
3-1.2純化具同位素15N、13C和2H標定ApoE195-299…………………19
3-1.3藉由NMR 分ApoE195-299之立體結構…………………………..21
3-2 ApoE3N與ApoE4N之製備…………………………………………….21
3-2.1 表達ApoE3N以及ApoE4N 融合蛋白.............................................21
3-2.2純化ApoE3N以及ApoE4N………………………………….……...22
3-2.3 以NMR分析15N和13C標定的ApoE3N之結果………………….23
3-3 D2O之再生與利用……………………………………………………….23
第四章 討論………………………………………………………………….24
第五章 參考文獻…………………………………………………………….27
附圖…………………………………………………………………………...31
附表…………………………………………………………………………...47
附錄…………………………………………………………………………...48

Aggerbeck L. P., W. J. R., Weisgraber K. H., Wu C. S., Lindgren F. T. (1988). Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem. 263, 6249-6258.

Bales K. R., D. J. C., DeMattos R. B., Holtzman D. M., Paul S. M. (2002). Apolipoprotein E, amyloid, and Alzheimer disease. Mol Interv. 2, 363-375.

Boyles J. K., P. R. E., Wilson E., Mahley R. W., Taylor J. M. (1985). Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 76, 1501-1513.

Corder E H, S. A. M., Risch N J, Strittmatter W J, Schmechel D E, Gaskell P C Jr, Rimmler J B, Locke P A, Conneally P M, Schmader KE, et al (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 7, 180-184.

Corder E. H., S. A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A.. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.

Das H. K., M. J., Bruns G. A., Karathanasis S. K., Breslow J. L. (1985). Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J Biol Chem 260, 6240-6247.


Diedrich J. F. , M. H., Carp R. I. , Whitaker J. N. ,Race R. , Frey W. , 2nd, and Haase A. T. (1991). Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. Journal of Virology 69, 4759-4768.

Dodart J. C., M. R. A., Koistinaho M., Gregersen B. M., Malkani S., Verma I. M., Paul S. M. (2005). Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci 102, 1211-1216.

Dong L. M., W. C., Wardell M. R., Simmons T., Mahley R. W., Weisgraber K. H., Agard D. A. (1994). Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem. 269, 22358-22365.

Ignatius M. J., G.-H. P. J., Skene J. H., Schilling J. W., Weisgraber K. H., Mahley R. W., Shooter E. M. (1986). Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci 83, 1125-1129.

Khachaturian (1985). Diagnosis of Alzheimer's disease. Arch Neurol. 42, 1097-1105.

LaDu M. J., P. M., Frail D. E., Reardon C. A., Getz G. S., Falduto M. T. (1995). Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem. 270, 9039-9042.

Mahley R. W., I. T. L., Rall SC Jr., Weisgraber K. H. (1984). Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 25, 1277-1294.

Menzel H. J., K. R. G., Assmann G. (1983). Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis 3, 310-315.

Rall S. C. Jr., W. K. H., Mahley R. W. (1982.). Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 257, 4171-4178.

Russo C., A. G., Dapino D., Piccini A., Piombo G., Schettini G., Chen S., Teller J. K., Zaccheo D., Gambetti P., Tabaton M. (1998). Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc Natl Acad Sci 95, 15598-15602.

Steinmetz A., J. C., Motzny S., Kaffarnik H. (1989). Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis 9, 405-11.

Strittmatter W. J., R. A. D. (1995). Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci 92, 4725-4727.

Strittmatter W. J., S. A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D. (1993A). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90, 1977-1981.

Strittmatter W. J., W. K. H., Huang D. Y., Dong L. M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunders A. M., Goldgaber D., Roses A. D. (1993B). Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci 90, 8098-8102.

Weisgraber K. H., R. S. C. J., Mahley R. W. (1981). Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 256, 9077-9083.

Weisgraber K. H., I. T. L., Harder K. J., Mahley R. W., Milne R. W., Marcel Y. L., Sparrow J. T. (1983). The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem. 258, 12348-12354.

Weisgraber K. H. (1990.). Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res. 31, 1503-1511.

Weisgraber K. H., M. R. W. (1996). Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 10, 1485-1494.

Westerlund J. A., W. K. H. (1993). Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J Biol Chem. 268, 15745-15750.

Wetterau J. R., A. L. P., Rall SC. Jr., Weisgraber K. H. (1988). Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem. 263, 6240-6248.

Wilson C., W. M. R., Weisgraber K. H., Mahley R. W., Agard D. A. (1991). Three- dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252, 1817-1822.